News

Qubigen is pleased to announce that its CEO, Dr Jonathan Hall, and its Chief Information Officer, A/Prof Dr Jun Zeng, will be presenting at the Walter and Eliza Hall Institute of Medical Research (WEHI) Divisional Seminar Program . Hosted by Professor Guillaume Lessene,   the seminar will explain how Qubigen’s proprietary Federated AI Platform (FedAIDD) is enabling a new paradigm in collaborative drug design. Date Thursday, 20 November 2025 Time 10:45 to 11:45 AM Location WEH

Qubigen Pty Ltd is pleased to announce that it has entered into an agreement with Rio Pharmaceuticals , Inc., a San Francisco-based biotechnology company focused on developing imaging tracers for the diagnosis and staging of neurological disease. This agreement marks Rio’s first expansion into therapeutics, launching a multi-stage development program with Qubigen to develop novel small molecule therapeutics targeting a critical pathway in neurological diseases.   Combining AI

Qubigen is pleased to share that its CEO, Dr. Jonathan Hall, will be a featured speaker at the upcoming Society for Bioinformatics and...